Recruiting
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.
ClinicalTrials.gov IDNCT05551104
PhasePHASE3
Enrollment500
SponsorLoma Linda University
Age18 Years
SexFEMALE
Conditions studied
Postpartum Complication, Maternal Hypertension, High Blood Pressure
About this study
The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.
Interventions
- Drug: Oral Nifedipine — Administration of oral nifedipine to control postpartum hypertension.
- Drug: Oral Labetalol — Administration of oral labetalol to control postpartum hypertension.
Primary outcomes
- Composite maternal morbidity (0-6 weeks following delivery)
Eligibility information
Inclusion Criteria:
* Female
* Women who develop postpartum hypertension\* after delivery of the placenta or chronic hypertensive postpartum women who require medication for blood pressure control.
* Postpartum hypertension requiring treatment are defined as systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure greater than or equal to 90mmHg on at least 2 occasions at least 4 hours apart, or systolic blood pressure greater than or equal to 160mmHg or diastolic blood pressure greater than 110mmHg sustained for more than 15 minutes.
Exclusion Criteria:
* History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema
* Contraindication to either Nifedipine or Labetalol
* HR \<60 or \>110
* Native language other than English or Spanish
Study locations
- Loma Linda University Health, Loma Linda, California 92350 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.